Lotus Eye Hospital and Institute Limited is a premier super-specialty ophthalmic healthcare provider headquartered in Coimbatore, India. Operating a **single-segment business model** focused exclusively on **Eye Care and Related Activities**, the company provides a full spectrum of tertiary services ranging from routine examinations to advanced robotic and laser-assisted surgical procedures. With a clinical history of screening over **1 Crore eyes** and performing **2 Lakh+ surgeries**, the institute combines a "hi-tech" clinical model with a commitment to affordable, world-class eye care. --- ### **Geographic Footprint and Infrastructure Hubs** The company currently operates a network of **10 Eye Care centers** strategically positioned across the South Indian states of Tamil Nadu and Kerala. The infrastructure strategy utilizes a mix of owned flagship properties and leased satellite clinics. | State | Locations | Infrastructure Type | |:---|:---|:---| | **Tamil Nadu** | Coimbatore (Peelamedu, R.S. Puram, Saravanampatti), Salem, Tirupur, Mettupalayam, Karur, Gobichettipalayam | Peelamedu & R.S. Puram are **Owned**; others are **Leased**. | | **Kerala** | Kochi (Kadavanthra), Mulanthuruthy | Leased | * **Revenue Concentration:** The **Peelamedu (Sitra) branch** remains the primary operational engine, contributing approximately **40% of total corporate revenue**. * **Modernization Initiatives:** In 2024, the company completed significant renovations at the **Salem** and **Cochin** branches to modernize surgical suites and patient facilities. * **Expansion Velocity:** After a decade of stagnant footprint growth, the company has entered an aggressive expansion phase, opening the **Saravanampatti** branch (July 2023), the **Karur** branch (July 2024), and the **Gobichettipalayam** branch (October 2025). --- ### **Clinical Specializations and Technological Leadership** Lotus Eye Hospital distinguishes itself through the early adoption of advanced ophthalmic hardware, positioning itself as a technology leader in the region. #### **Core Service Segments** * **Refractive Surgery:** Specializing in "lens-free" solutions including **SMILE**, **Touch-free LASIK**, Bladeless LASIK, and Zyoptix Ultimate. * **Cataract & Cornea:** Utilizing **LRCS (Laser Refractive Cataract Surgery)** and Phacoemulsification (MICS/SICS). Advanced corneal procedures include Penetrating Keratoplasty (PKP) and C3R for Keratoconus. * **Vitreoretinal Services:** High-complexity surgeries including Vitrectomy and Membrane Peeling, supported by advanced pharmacotherapy (Lucentis, Accentrix, Eyelea). * **Specialized Clinics:** Dedicated units for Glaucoma, Oculoplasty (Ptosis, DCR), and a specialized **Diabetic Eye Unit**. #### **Technological Milestones** The company has a history of regional "firsts," including the introduction of **Phacoemulsification** (1994) and **Epilasik** (2004). Recent upgrades include the launch of **Touch-free Glass-free Smart Lasik** in Kochi and Salem, providing a competitive edge over local private practitioners. --- ### **Strategic Growth and Market Positioning** The company’s strategy is built on a **Hub-and-Spoke model**, balancing high-end urban centers with accessible district clinics to address the "urban-rural differential" in healthcare access. * **Expansion Outlook:** Management plans to continue exploring new centers across Tamil Nadu and Kerala over the next **5 years**. New centers are targeted to achieve **operational breakeven within 18-24 months**. * **Academic Integration:** To ensure a steady pipeline of talent, the company operates the **Lotus Bausch & Lomb Institute of Optometry** and offers **DNB Courses** and Fellowship Programs. * **Community Engagement:** The company maintains a strong social license through free Sunday eye camps under the **Chief Minister’s scheme** and the **Life Time Vision Project**. * **Listing Strategy:** In **March 2026**, the Board reaffirmed its commitment to public markets by deciding **not to proceed** with a voluntary delisting from the **NSE**. The company remains listed on both the **BSE and NSE**. --- ### **Financial Profile and Capital Allocation** Lotus Eye Hospital maintains a conservative financial philosophy, characterized by a **100% debt-free balance sheet**. #### **Comparative Financial Performance** | Metric (Rs. in Crore) | FY 2024-25 (Est/Partial) | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **49.56** | **48.21** | **47.04** | | **Net Profit** | - | **2.92** | **4.08** | | **Net Profit Margin** | - | **5.89%** | **8.46%** | | **EBITDA Margin** | - | **16%** | - | | **Surgical Volume** | - | - | **9,703** | #### **Capital Structure and Liquidity** * **Equity Base:** Paid-up equity capital stands at **₹20.80 Crores** (**2,07,96,330 shares** at ₹10 par). * **Profitability Pressures:** While revenue is growing, net margins in FY24 were impacted by a **₹93 lakh** increase in manpower costs, a **₹75 lakh** rise in depreciation from new assets, and higher government electricity tariffs. * **Investment Strategy:** The company invested **₹5.57 Crores** in capital expenditure in FY25, funded entirely through internal accruals. Management targets an improved **EBITDA margin of 20% - 25%** as new branches scale. * **Dividend Policy:** A dividend of **₹0.50 per share** was declared in 2023; however, no dividend was declared for FY 2024-25 to preserve cash for expansion. --- ### **Risk Management and Governance** The company operates under a risk management framework governed by **NBEMS** standards, addressing both clinical and corporate risks. #### **Regulatory and Governance Challenges** * **Compliance Oversight:** The company recently faced **BSE/NSE** scrutiny regarding **Regulation 17(1A)** for failing to seek timely shareholder approval via special resolution for the continuation of **Dr. KS Ramalingam** as a Non-Executive Director. * **Insider Trading:** In **December 2023**, the Audit Committee levied a **₹10,00,000 penalty** on a designated person for a contra-trade violation involving **2,07,000 shares**. * **Contingent Liabilities:** As of March 2025, the company faces **₹82.17 Lakhs** in contingent liabilities, primarily related to **Income Tax demands (₹55.40 Lakhs)** and **Kerala VAT (₹26.77 Lakhs)**. #### **Operational Risks** * **Talent War:** A significant shortage of ophthalmologists and para-medical staff, coupled with aggressive poaching by commercial chains, poses a risk to operational continuity. * **Technological Obsolescence:** The rapid rise of **Artificial Intelligence (AI)** in diagnostics requires continuous capital reinvestment to prevent service obsolescence. * **Market Fragmentation:** Competition remains high from both low-cost unorganized clinics and large-scale philanthropic hospitals. The company counters this by maintaining **"world-class" standards at affordable price points**.